Cdc20 turnover rate: A key determinant in cancer patient response to anti‐mitotic therapies?

Publisher： John Wiley & Sons Inc

E-ISSN： 1521-1878|35|9|762-762

ISSN： 0265-9247

Source： BIOESSAYS (ELECTRONIC), Vol.35, Iss.9, 2013-09, pp. : 762-762

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dengue severity: a key determinant of underreporting

By  

TROPICAL MEDICINE & INTERNATIONAL HEALTH, Vol. 20, Iss. 10, 2015-10 ,pp. : 1403-1403

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic variation in the DNA repair pathway as a potential determinant of response to platinum‐based chemotherapy in breast cancer

By  

JOURNAL OF CELLULAR PHYSIOLOGY, Vol. 233, Iss. 4, 2018-04 ,pp. : 2752-2758

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cdc42: Role in Cancer Management

By  

CHEMICAL BIOLOGY & DRUG DESIGN (ELECTRONIC), Vol. 86, Iss. 4, 2015-10 ,pp. : 432-439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cdc42: Role in Cancer Management

By  

CHEMICAL BIOLOGY & DRUG DESIGN (ELECTRONIC), Vol. 1747-0277, Iss. 4, 2015-10 ,pp. : 432-439

John Wiley & Sons Inc

Access to resources Recommend Favorite

99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies

By Schaper Frédéric L.W.V.J.   Reutelingsperger Chris P.  

Cancers, Vol. 5, Iss. 2, 2013-05 ,pp. : 550-568

MDPI

Access to resources Recommend Favorite